Prothena plc Net Income
| PRTA Stock | USD 9.06 0.08 0.88% |
As of the 30th of January, Prothena Plc holds the Risk Adjusted Performance of (0.01), variance of 8.99, and Coefficient Of Variation of (3,841). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Prothena Plc, as well as the relationship between them.
Prothena Plc Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 14.4447 | Revenue | Earnings Share (5.20) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -110.1 M | -115.6 M | |
| Net Loss | -110.1 M | -115.6 M | |
| Net Loss | -105.3 M | -110.5 M | |
| Net Loss | (2.62) | (2.75) | |
| Net Income Per E B T | 0.95 | 1.09 |
Prothena | Net Income | Build AI portfolio with Prothena Stock |
Analyzing Prothena Plc's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Prothena Plc's current valuation and future prospects.
Latest Prothena Plc's Net Income Growth Pattern
Below is the plot of the Net Income of Prothena plc over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Prothena plc financial statement analysis. It represents the amount of money remaining after all of Prothena plc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Prothena Plc's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Prothena Plc's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (122.31 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Prothena Net Income Regression Statistics
| Arithmetic Mean | (83,241,526) | |
| Geometric Mean | 69,659,108 | |
| Coefficient Of Variation | (76.65) | |
| Mean Deviation | 52,106,966 | |
| Median | (110,079,000) | |
| Standard Deviation | 63,801,549 | |
| Sample Variance | 4070.6T | |
| Range | 227.1M | |
| R-Value | (0.43) | |
| Mean Square Error | 3532.2T | |
| R-Squared | 0.19 | |
| Significance | 0.08 | |
| Slope | (5,456,303) | |
| Total Sum of Squares | 65130.2T |
Prothena Net Income History
Other Fundumenentals of Prothena plc
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Prothena Plc Net Income component correlations
Prothena Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Prothena Plc is extremely important. It helps to project a fair market value of Prothena Stock properly, considering its historical fundamentals such as Net Income. Since Prothena Plc's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Prothena Plc's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Prothena Plc's interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. Anticipated expansion of Prothena directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Prothena Plc assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (5.20) | Revenue Per Share | Quarterly Revenue Growth 1.49 | Return On Assets | Return On Equity |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prothena Plc's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prothena Plc should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prothena Plc's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Prothena Plc 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Prothena Plc's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Prothena Plc.
| 11/01/2025 |
| 01/30/2026 |
If you would invest 0.00 in Prothena Plc on November 1, 2025 and sell it all today you would earn a total of 0.00 from holding Prothena plc or generate 0.0% return on investment in Prothena Plc over 90 days. Prothena Plc is related to or competes with Kalvista Pharmaceuticals, Bicycle Therapeutics, 4D Molecular, Verastem, Olema Pharmaceuticals, Ventyx Biosciences, and Neumora Therapeutics. Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for lif... More
Prothena Plc Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Prothena Plc's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Prothena plc upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 13.99 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 5.1 |
Prothena Plc Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Prothena Plc's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Prothena Plc's standard deviation. In reality, there are many statistical measures that can use Prothena Plc historical prices to predict the future Prothena Plc's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | (0.06) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Prothena Plc's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Prothena Plc January 30, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 2.36 | |||
| Coefficient Of Variation | (3,841) | |||
| Standard Deviation | 3.0 | |||
| Variance | 8.99 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 13.99 | |||
| Value At Risk | (4.36) | |||
| Potential Upside | 5.1 | |||
| Skewness | 0.4512 | |||
| Kurtosis | 0.0408 |
Prothena plc Backtested Returns
Prothena plc maintains Sharpe Ratio (i.e., Efficiency) of -0.0685, which implies the firm had a -0.0685 % return per unit of risk over the last 3 months. Prothena plc exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Prothena Plc's Coefficient Of Variation of (3,841), variance of 8.99, and Risk Adjusted Performance of (0.01) to confirm the risk estimate we provide. The company holds a Beta of 1.52, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Prothena Plc will likely underperform. At this point, Prothena plc has a negative expected return of -0.2%. Please make sure to check Prothena Plc's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Prothena plc performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.20 |
Weak predictability
Prothena plc has weak predictability. Overlapping area represents the amount of predictability between Prothena Plc time series from 1st of November 2025 to 16th of December 2025 and 16th of December 2025 to 30th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Prothena plc price movement. The serial correlation of 0.2 indicates that over 20.0% of current Prothena Plc price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.2 | |
| Spearman Rank Test | 0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Prothena Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Prothena plc reported net income of (122.31 Million). This is 135.84% lower than that of the Biotechnology sector and 274.61% lower than that of the Health Care industry. The net income for all United States stocks is 121.42% higher than that of the company.
Prothena Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Prothena Plc's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Prothena Plc could also be used in its relative valuation, which is a method of valuing Prothena Plc by comparing valuation metrics of similar companies.Prothena Plc is currently under evaluation in net income category among its peers.
Prothena Plc ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Prothena Plc's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Prothena Plc's managers, analysts, and investors.Environmental | Governance | Social |
Prothena Plc Institutional Holders
Institutional Holdings refers to the ownership stake in Prothena Plc that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Prothena Plc's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Prothena Plc's value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 933.4 K | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 693.2 K | Balyasny Asset Management Llc | 2025-06-30 | 575.8 K | Trexquant Investment Lp | 2025-06-30 | 552.8 K | Goldman Sachs Group Inc | 2025-06-30 | 528.3 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 501.8 K | Rock Springs Capital Management Lp | 2025-06-30 | 492.6 K | Granahan Investment Management Inc.. | 2025-06-30 | 461.1 K | Birchview Capital, Lp | 2025-06-30 | 451 K | Fmr Inc | 2025-06-30 | 7.9 M | Blackrock Inc | 2025-06-30 | 3.9 M |
Prothena Fundamentals
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.29 | ||||
| Operating Margin | (16.46) % | ||||
| Current Valuation | 170.25 M | ||||
| Shares Outstanding | 53.83 M | ||||
| Shares Owned By Insiders | 19.20 % | ||||
| Shares Owned By Institutions | 79.82 % | ||||
| Number Of Shares Shorted | 7.07 M | ||||
| Price To Earning | 37.12 X | ||||
| Price To Book | 1.67 X | ||||
| Price To Sales | 41.38 X | ||||
| Revenue | 135.16 M | ||||
| Gross Profit | (158.65 M) | ||||
| EBITDA | (153.67 M) | ||||
| Net Income | (122.31 M) | ||||
| Cash And Equivalents | 508.8 M | ||||
| Cash Per Share | 10.84 X | ||||
| Total Debt | 10.84 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 13.00 X | ||||
| Book Value Per Share | 5.48 X | ||||
| Cash Flow From Operations | (150.05 M) | ||||
| Short Ratio | 10.32 X | ||||
| Earnings Per Share | (5.20) X | ||||
| Price To Earnings To Growth | 0.80 X | ||||
| Target Price | 20.33 | ||||
| Number Of Employees | 163 | ||||
| Beta | -0.097 | ||||
| Market Capitalization | 487.7 M | ||||
| Total Asset | 547.11 M | ||||
| Retained Earnings | (1.1 B) | ||||
| Working Capital | 436.91 M | ||||
| Current Asset | 377.4 M | ||||
| Current Liabilities | 22.22 M | ||||
| Net Asset | 547.11 M |
About Prothena Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Prothena plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prothena Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prothena plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VTI | Vanguard Total Stock | |
| RIOT | Riot Blockchain | |
| TSLA | Tesla Inc |
Check out For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. Anticipated expansion of Prothena directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Prothena Plc assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (5.20) | Revenue Per Share | Quarterly Revenue Growth 1.49 | Return On Assets | Return On Equity |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Prothena Plc's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Prothena Plc should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Prothena Plc's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.